4.7 Article

Hydroxypropyl-beta-Cyclodextrin embedded resveratrol regulates gut microbiota to prevent NAFLD via activating AMPK signaling pathway

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Review Food Science & Technology

Intestinal dysbiosis in nonalcoholic fatty liver disease (NAFLD): focusing on the gut-liver axis

Hui Han et al.

Summary: Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver disorder that is closely related to gut dysfunction. The bidirectional communication between the gut and liver, mediated by metabolites, plays a role in the pathogenesis of NAFLD.

CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION (2023)

Article Biochemistry & Molecular Biology

Artemisinin hydroxypropyl-?-cyclodextrin inclusion complex loaded with porous starch for enhanced bioavailability

Wen Zhu et al.

Summary: This study aimed to enhance the oral bioavailability of ART by including it with HP-8-CD and then loaded with PS. The prepared AHPS showed higher solubility and bioavailability compared to ART and APT, and exhibited better antimalarial activity. This research provides a new idea for the development and application of fat-soluble drugs.

INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2022)

Article Food Science & Technology

Fisetin represses oxidative stress and mitochondrial dysfunction in NAFLD through suppressing GRP78-mediated endoplasmic reticulum (ER) stress

Xianling Dai et al.

Summary: The study revealed that Fisetin can efficiently attenuate NAFLD by restraining ROS generation and alleviating mitochondrial impairment.

JOURNAL OF FUNCTIONAL FOODS (2022)

Article Chemistry, Multidisciplinary

Prebiotic-like cyclodextrin assisted silybin on NAFLD through restoring liver and gut homeostasis

Ling Ren et al.

Summary: This study aimed to develop a silybin-2-hydroxypropyl-B-cyclodextrin inclusion (SHBCD) to improve the therapeutic efficacy of silybin (SLN) and elucidate the mechanisms of improvement in non-alcoholic fatty liver disease (NAFLD). The results showed that SHBCD improved drug permeability and bioavailability, modulated gut health, and exhibited superior anti-lipid accumulation, antioxidant, and anti-inflammatory effects compared with SLN alone.

JOURNAL OF CONTROLLED RELEASE (2022)

Review Medicine, General & Internal

Current treatment of non-alcoholic fatty liver disease

Rafael Paternostro et al.

Summary: Non-alcoholic fatty liver disease (NAFLD) is a liver disease with various pathologies. In addition to lifestyle changes and a few specific medications, there are new treatment options being studied. Treating complications of end-stage liver disease caused by non-alcoholic steatohepatitis (NASH) is important for the treatment of the complete clinical spectrum of NAFLD.

JOURNAL OF INTERNAL MEDICINE (2022)

Article Medicine, Research & Experimental

Downregulation of hepatic lipopolysaccharide binding protein improves lipogenesis-induced liver lipid accumulation

Jessica Latorre et al.

Summary: This study found that intervention on liver LBP can reduce liver lipid accumulation and oxidative stress, thus reducing the development of obesity-related fatty liver. However, in other circumstances, liver LBP downregulation does not have an impact on liver steatosis.

MOLECULAR THERAPY-NUCLEIC ACIDS (2022)

Review Chemistry, Medicinal

Resveratrol from Dietary Supplement to a Drug Candidate: An Assessment of Potential

Shivani Khattar et al.

Summary: Resveratrol is a well-known phytochemical that is widely used in dietary supplements and botanical products. It has a wide range of pharmacological effects, including antioxidant, anti-cancer, and anti-inflammatory activities, and can be used to treat multiple diseases. Establishing safety, efficacy profile, and physicochemical characterization are the major requirements for its development as a phyto-pharmaceutical.

PHARMACEUTICALS (2022)

Review Endocrinology & Metabolism

NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment

Giovanni Targher et al.

Summary: NAFLD is strongly associated with an increased risk of cardiovascular events and other cardiac complications, independently of traditional CVD risk factors. The risk of CVD and other cardiac/arrhythmic complications parallels the severity of NAFLD, with multiple underlying mechanisms likely contributing to this increased risk.

DIABETES & METABOLISM (2021)

Review Gastroenterology & Hepatology

Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention

Daniel Q. Huang et al.

Summary: The prevalence of NAFLD-related HCC is projected to continue rising globally, with NASH expected to increase and obesity as a major risk factor. Urgent measures are needed to address this growing problem.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)

Article Food Science & Technology

Flammulina velutipes mycorrhizae dietary fiber improves lipid metabolism disorders in obese mice through activating AMPK signaling pathway mediated by gut microbiota

Wenliang Wang et al.

Summary: Research shows that Flammulina velutipes dietary fiber can alleviate lipid metabolism disorders in obese mice by regulating the gut microbiota and activating the AMPK signaling pathway, leading to decreased lipid synthesis and increased lipid degradation.

FOOD BIOSCIENCE (2021)

Article Endocrinology & Metabolism

Supplementation of a propionate-producing consortium improves markers of insulin resistance in an in vitro model of gut-liver axis

Racha El Hage et al.

AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2020)

Article Gastroenterology & Hepatology

Nonalcoholic Fatty Liver Disease 2020: The State of the Disease

Thomas G. Cotter et al.

GASTROENTEROLOGY (2020)

Review Food Science & Technology

The influence of dietary patterns on gut microbiome and its consequences for nonalcoholic fatty liver disease

Qing-Song Zhang et al.

TRENDS IN FOOD SCIENCE & TECHNOLOGY (2020)

Article Pharmacology & Pharmacy

Berberine Improves Glucose and Lipid Metabolism in HepG2 Cells Through AMPKα1 Activation

Gang Ren et al.

FRONTIERS IN PHARMACOLOGY (2020)

Review Gastroenterology & Hepatology

Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders

Judith Aron-Wisnewsky et al.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)

Review Chemistry, Medicinal

Health benefits of resveratrol: Evidence from clinical studies

Akhand Pratap Singh et al.

MEDICINAL RESEARCH REVIEWS (2019)

Article Dentistry, Oral Surgery & Medicine

Influence of Porphyromonas gingivalis in gut microbiota of streptozotocin-induced diabetic mice

Anri Ohtsu et al.

ORAL DISEASES (2019)

Article Pharmacology & Pharmacy

Propionic acid counteracts the inflammation of human subcutaneous adipose tissue: a new avenue for drug development

Sa'ad Al-Lahham et al.

DARU-JOURNAL OF PHARMACEUTICAL SCIENCES (2019)

Review Neurosciences

Resveratrol and Brain Mitochondria: a Review

Fernanda Rafaela Jardim et al.

MOLECULAR NEUROBIOLOGY (2018)

Review Gastroenterology & Hepatology

short chain fatty acids as potential therapeutic agents in human gastrointestinal and inflammatory disorders

P. A. Gill et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)

Review Endocrinology & Metabolism

Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus

Giovanni Targher et al.

NATURE REVIEWS ENDOCRINOLOGY (2018)

Article Gastroenterology & Hepatology

Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease

Yaron Rotman et al.

Article Gastroenterology & Hepatology

Treatment of NAFLD with diet, physical activity and exercise

Manuel Romero-Gómez et al.

JOURNAL OF HEPATOLOGY (2017)

Review Endocrinology & Metabolism

Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota

Michael Doulberis et al.

METABOLISM-CLINICAL AND EXPERIMENTAL (2017)

Review Urology & Nephrology

Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease

Giovanni Targher et al.

NATURE REVIEWS NEPHROLOGY (2017)

Article Biochemistry & Molecular Biology

Modulation of gut microbiota contributes to curcumin-mediated attenuation of hepatic steatosis in rats

Wenhuan Feng et al.

BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2017)

Review Gastroenterology & Hepatology

The role of the gut microbiota in NAFLD

Christopher Leung et al.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2016)

Review Gastroenterology & Hepatology

Management of NAFLD: a stage-based approach

Mary E. Rinella et al.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2016)

Article Microbiology

Diet Dominates Host Genotype in Shaping the Murine Gut Microbiota

Rachel N. Carmody et al.

CELL HOST & MICROBE (2015)

Article Food Science & Technology

Resveratrol improves hepatic steatosis by inducing autophagy through the cAMP signaling pathway

Yong Zhang et al.

MOLECULAR NUTRITION & FOOD RESEARCH (2015)

Article Pharmacology & Pharmacy

Effect of resveratrol on experimental non-alcoholic steatohepatitis

Sara Heeboll et al.

PHARMACOLOGICAL RESEARCH (2015)

Article Endocrinology & Metabolism

The short chain fatty acid propionate stimulates GLP-1 and PYY secretion via free fatty acid receptor 2 in rodents

A. Psichas et al.

INTERNATIONAL JOURNAL OF OBESITY (2015)

Article Gastroenterology & Hepatology

Resveratrol Does Not Benefit Patients With Nonalcoholic Fatty Liver Disease

Veronique S. Chachay et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)

Article Gastroenterology & Hepatology

Obesity and Liver Disease The Epidemic of the Twenty-First Century

Kathleen E. Corey et al.

CLINICS IN LIVER DISEASE (2014)

Article Gastroenterology & Hepatology

Intestinal Microbiota in Patients With Nonalcoholic Fatty Liver Disease

Marialena Mouzaki et al.

HEPATOLOGY (2013)

Review Biochemistry & Molecular Biology

The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism

Gijs den Besten et al.

JOURNAL OF LIPID RESEARCH (2013)

Article Gastroenterology & Hepatology

The global NAFLD epidemic

Rohit Loomba et al.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2013)

Review Cardiac & Cardiovascular Systems

Gut-liver axis: The impact of gut microbiota on non alcoholic fatty liver disease

D. Compare et al.

NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2012)

Review Pharmacology & Pharmacy

Interactions of gut microbiota with functional food components and nutraceuticals

J. M. Laparra et al.

PHARMACOLOGICAL RESEARCH (2010)